Source comparison
Quick Comparison Table
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice with a molecular weight of 1,419 Da. Its primary mechanism involves VEGFR2 activation, nitric oxide synthesis (Akt-eNOS), and growth hormone receptor upregulation. It ha
This comparison does not assign a generated winner or score.
- BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice with a molecular weight of 1,419 Da. Its primary mechanism involves VEGFR2 activation, nitric oxide synthesis (Akt-eNOS), and growth hormone receptor upregulation. It has a half-life of less than 30 minutes (IV, animal data) and is primarily used for localized tissue repair (tendons, GI tract, ligaments). It is administered subcutaneously near the injury site or orally for GI applications, at a typical dose of 250 to 500 mcg per day. Its evidence base includes over 100 preclinical studies and 3 small human pilot studies. BPC-157 is not FDA-approved and is classified as a Category 2 bulk drug substance. It is prohibited by WADA under S0 (Non-Approved Substances).
- TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4, a ubiquitous human protein, with a molecular weight of 889 Da. Its primary mechanism involves G-actin sequestration, cell migration promotion, and integrin-linked kinase signaling. Its half-life is not precisely established, though systemic activity persists longer than the half-life alone suggests. It is primarily used for systemic recovery (muscle, flexibility, multi-site healing) and is administered subcutaneously at any site due to its systemic distribution, at a typical dose of 2 to 2.5 mg twice weekly during loading and 2 mg weekly for maintenance. Its evidence base includes extensive TB4 preclinical literature and Phase 2/3 clinical trials of TB4 formulations. TB-500 is not FDA-approved and is not formally listed on the FDA Category 2 bulk drug substances list. It is prohibited by WADA under S0 (Non-Approved Substances).